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Allergic rhinitis is an inﬂammatory disease characterized by nasal wall remodeling with intense inﬁltration of eosinophils and mast
cells/basophils. Matrix metalloproteinases (MMPs), MMP-2 and MMP-9, are the major proteolytic enzymes that induce airway
remodeling. These enzymes are also important in the migration of inﬂammatory cells through basement membrane components.
We evaluated whether tranilast (TR) could inhibit MMP production from nasal ﬁbroblasts in response to tumor necrosis factor-α
(TNF-α) stimulation in vitro. Nasal ﬁbroblasts (NF) were established from nasal polyp tissues taken from patients with allergic
rhinitis. NF (2×105 c e l l s / m L )w e r es t i m u l a t e dw i t hT N F - α in the presence of various concentrations of TR. After 24 hours, the
culture supernatants were obtained and assayed for MMP-2, MMP-9, TIMP-1, and TIMP-2 levels by ELISA. The inﬂuence of TR
on mRNA expression of MMPs and TIMPs in cells cultured for 12 hours was also evaluated by RT-PCR. TR at more than 5 ×
10−5 M inhibited the production of MMP-2 and MMP-9 from NF in response to TNF-α stimulation, whereas TIMP-1 and TIMP-2
productionwasscarcelyaﬀected.TRalsoinhibitedMMPmRNAexpressioninNFafterTNF-αstimulation.Thepresentdatasuggest
that the attenuating eﬀect of TR on MMP-2 and MMP-9 production from NF induced by inﬂammatory stimulation may underlie
the therapeutic mode of action of the agent in patients with allergic diseases, including allergic rhinitis.
INTRODUCTION
Allergic rhinitis is deﬁned as an inﬂammatory re-
sponse in the nasal mucosa and is characterized by
the clinical symptoms of sneezing, itching, congestion,
rhinorrhea, and nasal blockage, which make breathing
through the nose diﬃcult [1, 2]. Immunohistochemical
studies of nasal tissues on patients with allergic rhinitis
show the accumulation of eosinophils and basophils/mast
cells within the lamina propria and epithelium [3]. Fur-
thermore, nasal lavage also reveals the presence of numer-
ous eosinophils in patients with allergic rhinitis [4].
Although the mechanisms of circulating inﬂamma-
tory cell migration into the inﬂammatory sites are not
fully understood, much evidence suggests that inﬂamma-
tory cell adhesion and the degradation of extracellular
matrix (ECM) proteins are essential processes for the cell
recruitment [5]. The degradation of ECM proteins by in-
ﬂammatory cells is accomplished, in part, by the secretion
of matrix metalloproteinases (MMPs), like MMP-2 and
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MMP-9, that speciﬁcally degrade denatured collagen, na-
tive type IV and type V collagens, and elastin [6, 7]. Fur-
thermore, structural abnormalities such as ﬁbrosis, thick-
ening of the basement membrane, and sloughed-oﬀ ep-
ithelium with areas of epithelial metaplasia have been well
described in patients with allergic rhinitis [8, 9]. These
pathological changes are called tissue remodeling and are
caused by MMPs secreted from epithelial cells and ﬁ-
broblasts in addition to inﬁltrating inﬂammatory cells
[9,10,11].TheseMMPsarealsoresponsibleformicrovas-
cular permeability leading to edema and cell migration
and ECM remodeling at the site of inﬂammation [7, 10].
Several studies have demonstrated that corticos-
teroids, which are commonly used in the management of
allergic airway diseases including allergic rhinitis, can de-
crease the expression and release of MMPs from airway
epithelial cells and ﬁbroblasts in vivo and in vitro [12, 13,
14]. Fexofenadine hydrochloride, an H1-antihistamine,
has also been reported to inhibit the production of MMPs
from nasal ﬁbroblasts at therapeutic blood levels in vitro
[15]. In addition to this agent, drugs like tranilast (TR)
and disodium cromoglycate, which exert membrane-
stabilizingactivities[16],havebeenusedforthetreatment
andmanagementofallergicdiseaseswithremarkablesuc-
cess [17]. However, little information on the inﬂuence2005:3 (2005) Inﬂuence of Tranilast on MMP Production in Nasal Fibroblasts 151
of membrane stabilizers on MMP production is available
[18]. In the present study, we examined the eﬀect of TR
on MMP production in nasal ﬁbroblasts (NF) in response
to inﬂammatory stimulation in vitro.
MATERIALS AND METHODS
Chemicals
TR (Kissei Pharmaceutical Co Ltd, Matsumoto,
Japan) as a preservative-free pure powder was dissolved
in antibiotics-free RPMI-1640 medium (Sigma Chemi-
cals, Co Ltd, St Louis, Mo) supplemented with 10% heat-
inactivated fetal calf serum (RPMI-FCS; Flow Laborato-
ries, North Ride, Australia) at 10−2 M. This solution was
sterilized by passing through a 0.22µm ﬁlter and stored at
4◦C as a stock solution. All dilutions used in this study
were prepared from this stock solution. Recombinant
TNF-α (preservative free) was purchased from Chemi-
con International, Inc (Temecula, Calif) and diluted with
RPMI-FCS to produce a concentration of 50.0ng/mL.
Inductionofﬁbroblasts
To induce ﬁbroblasts from nasal polyps, ﬁve patients
(3 female and 2 male; 36.6 ± 9.4 years of age) with aller-
gic rhinitis were recruited at the Department of Otolaryn-
gology Showa University Hospital. All subjects were non-
smokers and had not been treated with oral antiallergic
agents for at least 2 months. Nasal polyps were obtained
during surgical operations from ﬁve patients after obtain-
ing their written informed consent. The study protocol
was approved by the Ethics Committee of Showa Uni-
versity. The tissues were rinsed several times with RPMI-
FCS that contained 500U penicillin, 500µg/mL strep-
tomycin, and 5.0µg/mL amphotericin B and were cut
into small pieces (approximately 1mm2). Diced speci-
mens were plated at a density of 10 pieces in 100mm tis-
sue culture dishes and covered with a cover slip adhered
to the dish with sterile vaseline. The dishes were then
placed in a humidiﬁed atmosphere containing 5% CO2 at
37◦C. When a monolayer of ﬁbroblast-like cells reached
conﬂuence, the explanted tissues were removed. The cells
were then trypsinized and replated at a concentration of
5 ×105 cells/mL into 100mm tissue culture dishes in a ﬁ-
nal volume of 10.0mL. The medium was changed every
3 days for 2–3 weeks until conﬂuence was attained. Sub-
sequently, the cells were split 1:2 at conﬂuence and pas-
saged [19, 20]. The cells were characterized with antibod-
ies against vimentine, cytokeratin, and ﬁbronectin using
ﬂuorescent microscopy (model no IX 70, OLYMPUS Co
Ltd, Tokyo, Japan) [20]. Fibroblast purity of the NF sam-
ples was more than 99%. After characterization, aliquots
ofcellsateachpassagewerefrozenandstoredinliquidni-
trogen. Since previous experiments had revealed that the
ability of cells to produce MMP-2, MMP-9, TIMP-1, and
TIMP-2 in response to TNF-α stimulation was similar for
3rd and 8th passages of cells [15], 7th to 10th passage NF
were used for the following experiments.
Cellculture
Fibroblasts were washed several times with RPMI-
FCS, introduced into each well of 24-well culture plates
in triplicate at a concentration of 2 × 105 cells/mL in a
volume of 1.0mL, and allowed to adhere for 2 hours. Af-
ter removing unattached and dead cells by gently washing
t h ew e l l sw i t hR P M I - F C S ,T N F - α and various concentra-
tions of TR were added to cell cultures simultaneously to
gi v eaﬁ n a lv o l u m eo f2 .0mL. The cells were then cultured
for 24 hours in a humidiﬁed atmosphere with 5% CO2 at
37◦C. After 24 hours, the culture medium was removed
a n ds t o r e da t−40◦C until use. To examine mRNA expres-
sion, the cells were cultured in a similar manner for 12
hours and stored at −80◦C until use. In another exper-
iment, cells were treated with various concentrations of
TR for 2 hours before the start of TNF-α stimulation; and
the cells were cultured in a similar manner.
AssayforMMPandTIMP
MMP-2, MMP-9, TIMP-1, and TIMP-2 levels in the
culture supernatants were assayed using commercially
available human MMP and TIMP ELISA test kits (Amer-
sham Biosciences, Bucks, UK) according to the manufac-
turer’s recommendations. The activities of MMP-2 and
MMP-9 in culture supernatants were also examined by
ELISA test kits (Amersham Biosciences) according to the
manufacturer’s instructions. The results are expressed as
the mean ng/mL ± standard error of duplicate assays for
the ﬁve subjects.
AssayformRNAexpression
mRNA was extracted from NF using µMACS mRNA
isolation kits (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany), according to the manufacturer’s instructions.
The ﬁrst-strand cDNA synthesis from 1.0µgm R N A
was performed using the SuperScript Preampliﬁcation
System for cDNA synthesis (Gibco BRL, Gaithersburg,
Md). The polymerase chain reaction (PCR) mixture
consisted of 1.0µL of sample cDNA solution, 3.3µLo f
10 × PCR buﬀer (Takara Shuzo Co Ltd, Shiga, Japan),
2.6µL of dNTP mixture (Takara Shuzo), 1.0µLo fb o t h
sense and antisense primers, 0.2µLo fT a qD N Ap o l y -
merase (Takara Shuzo), and distilled water to produce
aﬁ n a lv o l u m eo f3 0 µL. The primers used for RT-PCR
were 5 -AGATCTTCTTCTTCAAGGACCGGTT-3 
(sense) and 5 -GGCTGGTCAGTGGCTTGGGGTA-
3  (antisense) for MMP-2, 5 -
CCCACATTTGACGTCCAGAGAAGAA-3  (sense)
and 5 -GTTTTTGATGCTATTGGCTGAGATCCA-
3  (antisense) for MMP-9, 5 -
CTCGCTGGACGTTGGAGGAAAGAA-3  (sense)
and 5 -AGCCCATCTGGTACCTGTGGTTCA-3  (anti-
sense) for TIMP-2, and 5 -CGGAACCGCTCATTGCC-3 
and 5 -ACCCACACTGTGCCCATCTA-3  for β-actin
[13]. The PCR conditions were as follows: 4 minutes at
94◦C, followed by 30 cycles of 30 seconds at 94◦C, 30
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Cells were stimulated with various concentrations of TNF-α for 24 hours. MMP-2 and MMP-9 levels in the culture supernatants were
examined by ELISA. Data are expressed as the mean ng/mL ± SE of ﬁve diﬀerent subjects. ∗ means signiﬁcant (P<. 05) compared
with 0 control.
there was a DNA extension period of 4 minutes at 72◦C
[13]. The primers used for RT-PCR of TIMP-1 were
5 -CACCCACAGACGGCCTTCTGCAAT-3  (sense) and
5 -AGTGTAGGTCTTGGTGAAGCC-3  (antisense) [21].
The PCR conditions were as follows: 4 minutes at 95◦C,
followed by 35 cycles of 1 minute at 94◦C, 1 minute at
56◦C, and 1 minutes at 72◦C. After cycling, DNA was
extended in a similar manner [21]. Each PCR product
(10µL) was run on 3% agarose gels, visualized by UV
illuminator after SYBR Green (BioWhittaker Molecular
Applications, Rockland, Me) staining, and photographed.
The intensity of the mRNA levels was corrected using the
level of β-actin transcripts measured by a densitometer.
Statisticalanalysis
The statistical signiﬁcance of the diﬀerence between
the control and experimental data was analyzed using an
ANOVA, followed by Fisher’s PLSD test. A P value less




The ﬁrst set of experiments was designed to deter-
mine the optimum concentration of TNF-α required to
obtain the maximum production of MMPs from NF. NF
(2×105 cells/mL)werestimulatedwithvariousconcentra-
tions of TNF-α for 24 hours. MMP-2 and MMP-9 levels
in the culture supernatants were then assayed by ELISA.
As shown in Figure 1a, the stimulation of NF with TNF-
α at more than 10.0ng/mL (but not 5.0ng/mL) caused a
signiﬁcant increase in MMP-2 production. The ability of
NF to produce MMP-9 was also enhanced by the stim-
ulation of cells with TNF-α. The minimum concentra-
tion of TNF-α, causing a signiﬁcant production of MMP-
9, was 5.0ng/mL (Figure 1b). We then examined the in-
ﬂuence of TR on MMP production from NF stimulated
with TNF-α. The addition of TR at less than 2.5×10−5 M
didnotcausethesuppressionofMMP-2productionfrom
NF, which was increased by TNF-α stimulation. When TR
was added at concentrations of 5.0 × 10−5 Mo rh i g h e r ,
however, the ability of cells to produce MMP-2 after TNF-
α stimulation was signiﬁcantly suppressed Figure 2a.W e
further examined the inﬂuence of TR on MMP-9 produc-
tion from NF. As shown in (Figure 2b), low doses (0.5
and 2.5 × 10−5 M) of TR did not aﬀect MMP-9 produc-
tion from NF stimulated with TNF-α: MMP-9 levels in
the experimental culture supernatants were nearly identi-
cal (not signiﬁcant) to those in the control supernatants
(TNF alone). However, the addition of TR at concen-
trations of 5.0 × 10−5 M or higher signiﬁcantly inhibited
MMP-9 production from NF induced by TNF-α stimu-
lation (Figure 2b). The data in Figures 2c and 2d also
show that TR at more than 5.0 × 10−5 M could signiﬁ-
cantly suppress the activity of MMP-2 and MMP-9 in cul-
turesupernatants.Thefourthexperimentwasundertaken
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Figure 2. Inﬂuence of tranilast (TR) on the production of MMP-2 and MMP-9 from nasal ﬁbroblasts in response to TNF-α stimula-
tion and on their activities. Cells were stimulated with 10.0ng/mL TNF in the presence of various concentrations of TR for 24 hours.
Data are expressed as the mean ng/mL ± SE of ﬁve diﬀerent subjects. (a) MMP-2 levels; (b) MMP-9 levels; (c) MMP-2 activities. (d)
MMP-9 activities. ∗ means signiﬁcant (P<. 05) compared with TNF alone.
production from NF. The data in Figure 3 clearly show
thatadditionofTRtocellculturesstimulatedwithTNF-α
suppressed the production of both TIMP-1 and TIMP-2,
whenthecellsweretreatedwiththeagentat25.0×10−5 M.
However, lower doses of TR (less than 10.0 × 10−5 M)
could not exert suppressive eﬀect on TIMP-1 and TIMP-2
production (Figure 3). We ﬁnally examined whether pre-
treatment of cells with TR could also suppress the pro-
duction of MMPs and TIMPs from NF induced by TNF-α
stimulation.AsshowninFigures4aand4b,pre-treatment
with TR could suppress the production of MMP-2 and
MMP-9; and the signiﬁcant suppression was ﬁrstly noted
at 5.0 × 10−5 M. The data in Figures 4c and 4d also show
that pre-treatment with TR at more than 5.0 × 10−5 M
caused signiﬁcant suppression of MMP-2 and MMP-9
activities in culture supernatants. However, TR at 5 ×
10−5 M could not inhibit TIMP-1 and TIMP-2 produc-
tion from NF (Figure 5). The suppressive activity of TR
on TIMP-1 and TIMP-2 production was only observed




An additional set of experiments was performed to
examine possible mechanisms enabling TR to suppress
MMP-2 and MMP-9 production, but not TIMP-1 and
TIMP-2 production from NF stimulated with TNF-α.
Cells were cultured with 25.0ng/mL TNF-α in the pres-
ence of either 0, 2.5, or 5.0 × 10−5 M TR for 12 hours.
The levels of mRNA expression were then evaluated by
RT-PCR. Addition of TR at more than 5.0 × 10−5 Ms i g -
niﬁcantlysuppressedtheTNF-α-inducedenhancementin
MMP mRNA expression in NF (Figure 6). However, TR
did not reduce the levels of TIMP mRNA expression in
NF (Figure 7). These ﬁndings were conﬁrmed by graphs
showing the ratio of the target to the β-actin mRNA ex-
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Figure 3. Inﬂuence of tranilast (TR) on the production of TIMP-1 and TIMP-2 from nasal ﬁbroblasts in response to TNF-α stimu-
lation. Cells were stimulated with 10.0ng/mL TNF in the presence of various concentrations of TR for 24 hours. Data are expressed
as the mean ng/mL ± SE of ﬁve diﬀerent subjects. NS means not signiﬁcant (P>. 05); ∗ means signiﬁcant (P<. 05) compared with
TNF alone.
DISCUSSION
In the present study, we clearly demonstrated that TR
at5.0×10−5 M,whichislowerthantherapeutictissuelev-
els [21], could inhibit the production of both MMP-2 and
MMP-9 from NF with virtually no eﬀects on the produc-
tion of TIMP-1 and TIMP-2. In addition, this inhibitory
action of TR on MMP production is due, at least in part,
to its suppressive activity on MMP mRNA expression.
Allergic rhinitis is an inﬂammatory disorder of the
nasal mucosa and epithelium [1, 2, 3, 11]. Aeroallergen
exposure in patients with allergic rhinitis results in im-
mune cell activation within the nasal mucosa along with
activation of the resident epithelial and endothelial cells
[22, 24]. Structural changes within the nasal walls, in ad-
dition to classical inﬂammatory responses, have also been
reported in patients with allergic rhinitis. These struc-
tural changes include epithelial disruption, mucus gland
hypertrophy, enhanced mucosal collagen deposition, mu-
cosal myoﬁbroblast transformation, and increased matrix
protein deposition. These cellular events are now called
tissue remodeling and involve extensive alteration of tis-
sue ECM [8, 9]. ECM is involved in tissue homeostasis
and several pathologic conditions such as tumor inva-
sion, wound healing, and inﬂammation. Two groups of
proteins, MMPs, and their counterregulatory inhibitors,
TIMPs, are important factors for the maintenance of
ECM homeostasis. The MMPs are a large family of Ca2+-
activated, Zn2+-dependent endopeptidases that have the
ability to degrade various components of the ECM and
basement membrane [11, 23]. At least 23 members of the
MMP family have been characterized [11, 23]. Among
them, MMP-2 and MMP-9, also known as gelatinase A
and B, respectively, degrade basement membrane type IV
and type V collagen and denatured collagens [11, 23].
They can also degrade elastine, as they can also act as
elastases [11, 23]. These MMPs are produced by numer-
ous cell types, including ﬁbroblasts, macrophages, and
eosinophils and mediate the transmigration of inﬂamma-
tory cells through the basement membrane to propagate
inﬂammation [12, 24]. MMPs are also responsible for mi-
crovasular permeability leading to edema and enhanced
cell migration [12]. The ﬁndings of these reports suggest
that the attenuating eﬀect of TR on MMP-2 and MMP-9
production from NF induced by inﬂammatory stimula-
tion may underlie the clinical eﬃcacy of this therapeu-
tic agent in allergic diseases, including allergic rhinitis.
The activity of MMPs in the extracellular milieu is con-
trolled by speciﬁc and potent inhibitory proteins known
as TIMPs [25]. The present results clearly showed that TR
did not inhibit TIMP-1 and TIMP-2 production from NF
in response to TNF-α stimulation, suggesting that MMPs
secreted in small amounts during TR treatment are inac-
tivated by TIMP-1 and TIMP-2, and resulted in the fa-
vorable modiﬁcation of clinical symptoms arising from
ECM remodeling in patientsd with allergic rhinitis. The
administration of MMP inhibitor into mice reportedly
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Figure 4. Inﬂuence of pretreatment of nasal ﬁbroblast with tranilast (TR) on the production of MMP-2 and MMP-9 and their
activities. Cells were treated with various concentrations of TR for 2 hours and then stimulated with TNF-α (TNF) for 24 hours. Data
are expressed as the mean ng/mL ± SE of ﬁve diﬀerent subjects. ∗ means signiﬁcant (P<. 05) compared with TNF alone.
endothelial and epithelial basement membrane [26]. This
inhibitory action of the MMP inhibitor on cell migration
has been associated with its suppressive eﬀect on the ex-
pression of the adhesion molecules, ICAM-1 and VCAM-
1[5],whichareessentialforcellmigrationintoinﬂamma-
tory tissues. These reports suggest that the negative sup-
pressive eﬀe c to fT Ro nT I M P - 1a n dT I M P - 2p r o d u c t i o n
may contribute, at least in part, to the modiﬁcation of
clinical symptoms, when TR is given to patients with al-
lergic rhinitis.
TNF-α is well known as a multifunctional cytokine
that plays a role in inﬂammation, immunity, and a va-
riety of diseases. It is also accepted that TNF-α activates
severalcomponentsimplicatedincellularsignaltransduc-
tion. Binding of TNF-α to type 1 TNF receptor causes an
increase in intracellular Ca2+ concentrations through cal-
cium inﬂux [27], resulting in the activation of transcrip-
tional factors (NF-κB and AP-1), which are essential for
MMP production [28, 29]. TR has been reported to in-
hibitincreasesincellularCa2+ concentrationsthroughthe
suppression of Ca2+ inﬂux from the extracellular space
[30]. Judging from these reports, it seems reasonable to
speculate that TR may suppress Ca2+ inﬂux into NF stim-
ulated with TNF-α, thereby inhibiting the activation of
the transcriptional factors (NF-κB and AP-1) responsible
for inducing MMP mRNA expression. The present obser-
vations showing that MMP mRNA expression in NF was
suppressed by TR support this hypothesis.
Prostaglandins (PG), especially PGE1 and PGE2,h a v e
been reported to up regulate the production of MMPs in
synoviocytes[31,32]andgingivalﬁbroblasts[33]afterin-
ﬂammatory stimulation in vitro. PGs are also involved in
the production of MMPs from human pulp cells [34]a n d
prostate epithelial tumor cells [35]. The ﬁnding that TR
inhibited MMP-2 and MMP-9 production suggests that
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Figure 5. Inﬂuence of pretreatment of nasal ﬁbroblasts with tranilast (TR) on the production of TIMP-1 and TIMP-2. Cells were
treated with various concentrations of TR for 2 hours and then stimulated with TNF-α (TNF) for 24 hours. Data are expressed as the
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Figure 6. Inﬂuence of tranilast (TR) on mRNA expression of (b) MMP-2 and (c) MMP-9 in nasal polyp ﬁbroblasts after TNF-α
stimulation. Cells were stimulated with 10.0ng/mLTNF-α in the presence of various concentrations of TR for 12 hours. mRNA
expression was examined by RT-PCR. One representative photograph out of ﬁve diﬀerent subjects is shown. Densitometric analysis
of the results of RT-PCR is shown with the intensity of MMP-2 and MMP-9. ∗ means signiﬁcant (P<. 05) compared with TNF-α

























































































Figure 7. Inﬂuence of tranilast (TR) on mRNA expression of TIMP-1 and TIMP-2 in nasal polyp ﬁbroblasts after TNF-α stimulation.
Cells were stimulated with 10.0ng/mLTNF-α in the presence of various concentrations of TR for 12 hours. mRNA expression was
examined by RT-PCR. One representative photograph out of ﬁve diﬀerent subjects is shown. Densitometric analysis of the results of
RT-PCRisshownwiththeintensityofMMP-2andMMP-9.β-actinmRNAexpressionwasshowninFigure 6. ∗meansnotsigniﬁcant
(P<. 05) compared with TNF-α alone.
in MMP production in NF induced by TNF-α stimula-
tion, since TR is reported to decrease PGE2 formation in
monocytes after inﬂammatory stimulation [36].
It has been reported that TR decreased the ability of
a human ﬁbroblast cell line from gastric carcinoma, to
produce MMP-2, but not MMP-9 in response to trans-
forming growth factor-β in vitro, even when the agent
at 3 × 10−5 Mw a sa d d e dt oc e l lc u l t u r e s[ 37]. The rea-
sons for the discrepancy between this report and our data
are not clear at present. The diﬀerent cell sources of nasal
polyps and gastric carcinoma may be responsible for this
phenomenon, because the biological characteristics of ﬁ-





TR in allergic inﬂammatory diseases might be explained
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